Earnings
TD Cowen reiterates Boston Scientific stock Buy rating after cyber recovery
TD Cowen has reiterated its Buy rating and $56.00 price target for Boston Scientific (NYSE:BSX) after the medical device company reported substantial recovery from a recent cybersecurity incident. Distribution networks are largely restored, and key product shipments have resumed. Despite the operational recovery, 22 analysts have revised earnings downwards, highlighting ongoing financial impact assessments.